SageView Advisory Group
ANIK icon

SageView Advisory Group’s Anika Therapeutics ANIK Stock Holding History

SageView Advisory Group’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-465
Closed -$4.47K – 664
2025
Q4 		$4.47K Buy
+465
New +$4.45K ﹤0.01% 1996

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Boothbay Fund Management
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

SageView Advisory Group's ANIK Position: Q1 2026 in Review

SageView Advisory Group sold out of Anika Therapeutics (ANIK) in Q1 2026, closing a stake of 465 shares — an estimated $4.47K sold.

SageView Advisory Group first reported a position in ANIK in Q4 2025 and held it in 1 quarter. The position peaked at $4.47K in Q4 2025. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.

  • SageView Advisory Group reported no remaining Anika Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 465 Anika Therapeutics shares in Q1 2026, an estimated $4.47K.
  • SageView Advisory Group first reported a position in Anika Therapeutics in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's Anika Therapeutics position peaked at $4.47K in Q4 2025.
  • 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.